|
|
Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. [Article:21289622@PubMed] |
|
|
The aldehyde dehydrogenase 2 gene is associated with heroin dependence. Drug and alcohol dependence. 2011. Wang Tzu-Yun, et al. [Article:21723677@PubMed] |
|
|
Dopamine-related genes and spontaneous smoking cessation in ever-heavy smokers. Pharmacogenomics. 2011. Breitling Lutz P, et al. [Article:21806388@PubMed] |
|
|
Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. Pharmacogenomics. 2011. Hwang Rudi, et al. [Article:21332319@PubMed] |
|
|
Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. Pharmacogenomics. 2011. Hung Chin-Chuan, et al. [Article:21902500@PubMed] |
|
|
Pharmacogenetic testing to predict antipsychotic-induced weight gain: a systematic review. Pharmacogenomics. 2011. Risselada Arne J, et al. [Article:21843067@PubMed] |
|
|
Sexual dysfunction in male schizophrenia: influence of antipsychotic drugs, prolactin and polymorphisms of the dopamine D2 receptor genes. Pharmacogenomics. 2011. Zhang Xiang Rong, et al. [Article:21749219@PubMed] |
|
|
Analysis of 94 Candidate Genes and 12 Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia. The American journal of psychiatry. 2011. Greenwood Tiffany A, et al. [Article:21498463@PubMed] |
|
|
Dopamine D2 receptor polymorphisms and susceptibility to alcohol dependence in Indian males: a preliminary study. BMC medical genetics. 2010. Prasad Pushplata, et al. [Article:20146828@PubMed] |
|
|
An association analysis of circadian genes in anxiety disorders. Biological psychiatry. 2010. Sipilä Tessa, et al. [Article:20122683@PubMed] |
|
|
Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. [Article:20981002@PubMed] |
|
|
Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas. Expert opinion on drug metabolism & toxicology. 2010. Filopanti M, et al. [Article:19929252@PubMed] |
|
|
Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert opinion on pharmacotherapy. 2010. Lohoff Falk W, et al. [Article:20102306@PubMed] |
|
|
Intronic Polymorphisms Affecting Alternative Splicing of Human Dopamine D2 Receptor Are Associated with Cocaine Abuse. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2010. Moyer Robert A, et al. [Article:21150907@PubMed] |
|
|
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. Pharmacogenetics and genomics. 2010. Lencz Todd, et al. [Article:20664489@PubMed] |
|
|
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment. Pharmacogenetics and genomics. 2010. Hong Chen-Jee, et al. [Article:20375926@PubMed] |
|
|
PharmGKB summary: dopamine receptor D2. Pharmacogenetics and genomics. 2010. Mi Huaiyu, et al. [Article:20736885@PubMed] |
|
|
PharmGKB summary: very important pharmacogene information for CYP2B6. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. [Article:20648701@PubMed] |
|
|
Blood gene expression correlated with tic severity in medicated and unmedicated patients with Tourette Syndrome. Pharmacogenomics. 2010. Liao Isaac H, et al. [Article:21142917@PubMed] |
|
|
Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients. Pharmacogenomics. 2010. De Ruyck Kim, et al. [Article:20712524@PubMed] |
|
|
Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics. 2010. McCarthy Michael J, et al. [Article:21047205@PubMed] |
|
|
Pharmacogenomic implications of variants of monoaminergic-related genes in geriatric psychiatry. Pharmacogenomics. 2010. Shiroma Paulo R, et al. [Article:20860469@PubMed] |
|
|
Prospective association of dopamine-related polymorphisms with smoking cessation in general care. Pharmacogenomics. 2010. Breitling Lutz P, et al. [Article:20350135@PubMed] |
|
|
A genetic schizophrenia-susceptibility region located between the ANKK1 and DRD2 genes. Progress in neuro-psychopharmacology & biological psychiatry. 2010. Dubertret Caroline, et al. [Article:20138949@PubMed] |
|
|
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. The American journal of psychiatry. 2010. Zhang Jian-Ping, et al. [Article:20194480@PubMed] |
|
|
Pharmacogenetic analysis of the mGlu2/3 agonist LY2140023 monohydrate in the treatment of schizophrenia. The pharmacogenomics journal. 2010. Liu W, et al. [Article:21173788@PubMed] |
|
|
Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. The pharmacogenomics journal. 2010. Müller D J, et al. [Article:20714340@PubMed] |
|
|
Genetics of dopamine receptors and drug addiction: a comprehensive review. Behavioural pharmacology. 2009. Le Foll Bernard, et al. [Article:19179847@PubMed] |
|
|
Clozapine, GABA(B), and the treatment of resistant schizophrenia. Clinical pharmacology and therapeutics. 2009. Daskalakis Z J, et al. [Article:19626000@PubMed] |
|
|
Predicting age-specific dosing of antipsychotics. Clinical pharmacology and therapeutics. 2009. Uchida H, et al. [Article:19763115@PubMed] |
|
|
Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients. European journal of clinical pharmacology. 2009. Liu Ying-Zi, et al. [Article:19396436@PubMed] |
|
|
Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients. Journal of psychiatric research. 2009. Shen Yu-Chih, et al. [Article:18926547@PubMed] |
|
|
Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco. 2009. Munafò Marcus R, et al. [Article:19246443@PubMed] |
|
|
Association of the dopamine D2 receptor gene with alcohol dependence: haplotypes and subgroups of alcoholics as key factors for understanding receptor function. Pharmacogenetics and genomics. 2009. Kraschewski Adrian, et al. [Article:19603545@PubMed] |
|
|
Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. Pharmacogenetics and genomics. 2009. Doehring Alexandra, et al. [Article:19373123@PubMed] |
|
|
Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenetics and genomics. 2009. Calarge Chadi A, et al. [Article:19339912@PubMed] |
|
|
Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms. Pharmacogenomics. 2009. Gupta Meenal, et al. [Article:19207030@PubMed] |
|
|
Genetic modulation of the pharmacological treatment of pain. Pharmacology & therapeutics. 2009. Lötsch Jörn, et al. [Article:19615406@PubMed] |
|
|
Movement disorders associated with aripiprazole use: a case series. The International journal of neuroscience. 2009. Hall Deborah A, et al. [Article:19916856@PubMed] |
|
|
A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. The pharmacogenomics journal. 2009. Gassó P, et al. [Article:19506579@PubMed] |
|
|
Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. Journal of psychiatric research. 2008. Alenius Malin, et al. [Article:18086475@PubMed] |
|
|
Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Molecular psychiatry. 2008. Bakker P R, et al. [Article:18180754@PubMed] |
|
|
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature genetics. 2008. Allen Nicole C, et al. [Article:18583979@PubMed] |
|
|
Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2008. Childs Emma, et al. [Article:18305461@PubMed] |
|
|
Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenetics and genomics. 2008. Kohlrausch Fabiana B, et al. [Article:18551040@PubMed] |
|
|
Taq1A polymorphism in the dopamine D2 receptor gene predicts brain metabolic response to aripiprazole in healthy male volunteers. Pharmacogenetics and genomics. 2008. Kim Euitae, et al. [Article:18192895@PubMed] |
|
|
Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics. Pharmacogenomics. 2008. Thelma Bk, et al. [Article:18781856@PubMed] |
|
|
Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics. 2008. Ikeda Masashi, et al. [Article:18855532@PubMed] |
|
|
Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Progress in neuro-psychopharmacology & biological psychiatry. 2008. Crettol Séverine, et al. [Article:18687376@PubMed] |
|
|
Relation between obesity and blunted striatal response to food is moderated by TaqIA A1 allele. Science (New York, N.Y.). 2008. Stice E, et al. [Article:18927395@PubMed] |
|
|
Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. The pharmacogenomics journal. 2008. Filopanti M, et al. [Article:18332900@PubMed] |
|
|
Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Molecular psychiatry. 2007. Zai C C, et al. [Article:17767146@PubMed] |
|
|
Association analysis of the dopamine receptor D2 (DRD2) SNP rs1076560 in alcoholic patients. Neuroscience letters. 2007. Sasabe Toshikazu, et al. [Article:17196743@PubMed] |
|
|
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenetics and genomics. 2007. Aklillu Eleni, et al. [Article:18075468@PubMed] |
|
|
The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2007. Xing Qinghe, et al. [Article:17105675@PubMed] |
|
|
The DRD2 TaqI-B polymorphism and its relationship to smoking abstinence and withdrawal symptoms. The pharmacogenomics journal. 2007. Robinson J D, et al. [Article:17189962@PubMed] |
|
|
Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. Journal of clinical psychopharmacology. 2006. Hedenmalm Karin, et al. [Article:16633151@PubMed] |
|
|
Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2006. Lerman Caryn, et al. [Article:16123753@PubMed] |
|
|
DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients. The American journal of psychiatry. 2006. Lencz Todd, et al. [Article:16513877@PubMed] |
|
|
Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatric disease and treatment. 2005. Lotrich Francis E, et al. [Article:18568127@PubMed] |
|
|
Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients. Neuroscience letters. 2005. Wu Shengnan, et al. [Article:15694263@PubMed] |
|
|
Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Progress in neuro-psychopharmacology & biological psychiatry. 2005. Corripio Iluminada, et al. [Article:15610950@PubMed] |
|
|
Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. Psychopharmacology. 2005. Hwang Rudi, et al. [Article:15830237@PubMed] |
|
|
D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2003. Noble Ernest P. [Article:12497624@PubMed] |
|
|
Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Human molecular genetics. 2003. Duan Jubao, et al. [Article:12554675@PubMed] |
|
|
Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. The pharmacogenomics journal. 2003. Yamanouchi Y, et al. [Article:14610521@PubMed] |
|
|
The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients. Pharmacogenetics. 2001. Suzuki A, et al. [Article:11505224@PubMed] |
|
|
Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics. 2000. Makoff A J, et al. [Article:10739171@PubMed] |
|
|
A global survey of haplotype frequencies and linkage disequilibrium at the DRD2 locus. Human genetics. 1998. Kidd K K, et al. [Article:9760208@PubMed] |
|
|
Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. Pharmacogenetics. 1998. Arranz M J, et al. [Article:9918131@PubMed] |
|
|
Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia. Psychiatry research. 1998. Ohara K, et al. [Article:9858029@PubMed] |
|
|
Dopamine D2 receptors in signal transduction and behavior. Critical reviews in neurobiology. 1997. Picetti R, et al. [Article:9209827@PubMed] |
|
|
A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Human molecular genetics. 1997. Arinami T, et al. [Article:9097961@PubMed] |
|
|
Evolution of haplotypes at the DRD2 locus. American journal of human genetics. 1995. Castiglione C M, et al. [Article:8533775@PubMed] |
|
|
Linkage disequilibria at the D2 dopamine receptor locus (DRD2) in alcoholics and controls. Genomics. 1994. Suarez B K, et al. [Article:7910578@PubMed] |
|
|
No structural mutation in the dopamine D2 receptor gene in alcoholism or schizophrenia. Analysis using denaturing gradient gel electrophoresis. JAMA : the journal of the American Medical Association. 1994. Gejman P V, et al. [Article:8277546@PubMed] |
|
|
Schizophrenia: normal sequence in the dopamine D2 receptor region that couples to G-proteins. DNA polymorphisms in D2. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 1993. Seeman P, et al. [Article:8471125@PubMed] |
|
|
Detection and characterization of additional DNA polymorphisms in the dopamine D2 receptor gene. Genomics. 1991. Hauge X Y, et al. [Article:1679742@PubMed] |
|
|
Direct sequencing of the dopamine D2 receptor (DRD2) in schizophrenics reveals three polymorphisms but no structural change in the receptor. Genomics. 1991. Sarkar G, et al. [Article:1837284@PubMed] |
|
|
A new TaqI RFLP within intron 2 of human dopamine D2 receptor gene (DRD2). Nucleic acids research. 1991. Parsian A, et al. [Article:1684859@PubMed] |
|
|
Population and pedigree studies reveal a lack of association between the dopamine D2 receptor gene and alcoholism. JAMA : the journal of the American Medical Association. 1990. Bolos A M, et al. [Article:1979357@PubMed] |
|
|
The human dopamine D2 receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. American journal of human genetics. 1989. Grandy D K, et al. [Article:2573278@PubMed] |
|
|
Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature. 1989. Giros B, et al. [Article:2531847@PubMed] |
|
|
Cloning of the cDNA and gene for a human D2 dopamine receptor. Proceedings of the National Academy of Sciences of the United States of America. 1989. Grandy D K, et al. [Article:2532362@PubMed] |